COMMUNIQUÉS West-GlobeNewswire

Tilray Medical Applauds German Bundestag and Landmark Passage of Medical Cannabis Act in Germany

23/02/2024 - 16:38

New Medical Cannabis Act in Germany Provides Easier Access to Medical Cannabis for Patients Through the MedCanG COLOGNE, Germany and NEUMÜNSTER, Germany, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray [...]

VITAS® Healthcare Continues Its Pathway of Success and Promotes Two Key Operations Executives

23/02/2024 - 16:31

MIAMI, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Two executive leaders at VITAS Healthcare have been promoted to top operational roles. Joel Wherley now serves as president and chief operating officer (COO) and Bryan Wysong as [...]

Curai Health to Expand Access to Care for Individuals Experiencing Homelessness

23/02/2024 - 16:21

LOS ANGELES, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Today, Curai Health , a virtual clinic, announced that it is expanding access to high-quality care for individuals experiencing homelessness. In collaboration with [...]

AVITA Medical to Host Investor Webinar Briefing

23/02/2024 - 15:01

VALENCIA, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin [...]

Strainsforpains Inc. Announces Corporate Update

23/02/2024 - 15:00

NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- (Strainsforpains, Inc.) (OTC Markets: EBYH). Strainsforpains is pleased to announce that it has increased the capacity of its Pennsylvania facility to accommodate the company’ [...]

Curia Appoints Steve Lavezoli as Vice President, Biologics

23/02/2024 - 15:00

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective [...]

Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business

23/02/2024 - 15:00

EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business. On December 14, 2023, the [...]

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Lunch Break: The Autonomix Opportunity

23/02/2024 - 14:50

Live webcast with Lori Bisson, Chief Executive Officer of Autonomix, on Thursday, February 29 th at 12:00 PM ET THE WOODLANDS, TX, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or [...]

Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

23/02/2024 - 14:30

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update Median Overall Survival of 16.5 Months [...]

Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

23/02/2024 - 14:00

REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) [...]

Venus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

23/02/2024 - 14:00

TORONTO, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive [...]

SAB Biotherapeutics to Present at the BIO CEO & Investor Conference

23/02/2024 - 14:00

SIOUX FALLS, S.D., Feb. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing [...]

Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

23/02/2024 - 14:00

Expanded access program (EAP) data for omidubicel are consistent with Phase 3 trial results on rates of hematopoietic recovery and infections following stem cell transplant with Omisirge ® (omidubicel-onlv) Preliminary [...]

Ocuphire Pharma to Present in the BIO CEO & Investor Conference

23/02/2024 - 14:00

FARMINGTON HILLS, Mich., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small- [...]

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update

23/02/2024 - 13:30

Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Wednesday, [...]

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

23/02/2024 - 13:06

For the first time, patients with alcohol use disorder will receive the company's unique and proprietary psychedelic - MEAI Vancouver, Canada, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND [...]

Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy

23/02/2024 - 13:05

Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe Positive CHMP opinion is [...]

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

23/02/2024 - 13:00

SOD1 -ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe 1 With QALSODY, Biogen has advanced the role of neurofilament in the development of new [...]

BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment

23/02/2024 - 13:00

RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new analyses of real-world use of oral, once-daily ORLADEYO ® (berotralstat) that showed [...]